AR116669A1 - Kits y métodos para tratar cánceres - Google Patents
Kits y métodos para tratar cánceresInfo
- Publication number
- AR116669A1 AR116669A1 ARP190102610A ARP190102610A AR116669A1 AR 116669 A1 AR116669 A1 AR 116669A1 AR P190102610 A ARP190102610 A AR P190102610A AR P190102610 A ARP190102610 A AR P190102610A AR 116669 A1 AR116669 A1 AR 116669A1
- Authority
- AR
- Argentina
- Prior art keywords
- kits
- methods
- treat cancers
- crystalline form
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Un kit que contiene una forma cristalina de un compuesto de quinazolina. Más particularmente, la forma cristalina deriva de 1-(4-(4-(3,4-dicloro-2-fluorofenilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)prop-2-en-1-ona. También se describe un método para tratar cánceres con la forma cristalina o un kit de esta.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862731500P | 2018-09-14 | 2018-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR116669A1 true AR116669A1 (es) | 2021-06-02 |
Family
ID=69776732
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190102610A AR116669A1 (es) | 2018-09-14 | 2019-09-16 | Kits y métodos para tratar cánceres |
ARP190102611A AR116406A1 (es) | 2018-09-14 | 2019-09-16 | Formas cristalinas de un compuesto de quinazolina y sus sales de clorhidrato |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190102611A AR116406A1 (es) | 2018-09-14 | 2019-09-16 | Formas cristalinas de un compuesto de quinazolina y sus sales de clorhidrato |
Country Status (16)
Country | Link |
---|---|
US (2) | US11883402B2 (es) |
EP (2) | EP3849557A4 (es) |
JP (2) | JP2022500456A (es) |
KR (2) | KR20210061371A (es) |
CN (2) | CN112770758A (es) |
AR (2) | AR116669A1 (es) |
AU (2) | AU2019337640A1 (es) |
BR (2) | BR112021004527A2 (es) |
CA (2) | CA3111062A1 (es) |
IL (2) | IL281167A (es) |
MX (2) | MX2021002875A (es) |
PH (2) | PH12021550432A1 (es) |
SG (2) | SG11202102006YA (es) |
TW (2) | TW202027750A (es) |
UY (2) | UY38375A (es) |
WO (2) | WO2020053816A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020053816A1 (en) | 2018-09-14 | 2020-03-19 | Hanmi Pharmaceutical Co., Ltd. | Crystalline forms of a quinazole compound and its hydrochloride salts |
CN114642728A (zh) * | 2021-06-02 | 2022-06-21 | 德琪(浙江)医药科技有限公司 | mTOR抑制剂的制药用途及其药物组合物 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2514092C (en) * | 2003-01-21 | 2013-03-19 | S.S.C.I., Inc. | Novel cocrystallization of hydrochloric acid salt of an active agent |
KR100735639B1 (ko) * | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
TW200640904A (en) * | 2005-02-26 | 2006-12-01 | Astrazeneca Ab | Quinazoline derivatives |
BRPI0712720A2 (pt) * | 2006-05-31 | 2012-11-20 | Abbott Lab | compostos tiazàis como ligantes do receptor canabinàide e usos dos mesmos |
CN101547910A (zh) | 2006-07-28 | 2009-09-30 | 合成纤维有限公司 | 结晶埃罗替尼 |
PT2170844T (pt) * | 2007-02-21 | 2016-08-05 | Natco Pharma Ltd | Novos polimorfos de cloridrato de erlotinib e método de preparação |
TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
KR101217526B1 (ko) * | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
KR101317809B1 (ko) * | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
KR101272613B1 (ko) * | 2011-10-05 | 2013-06-10 | 한미사이언스 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체 |
KR101645112B1 (ko) * | 2013-03-06 | 2016-08-02 | 아스트라제네카 아베 | 표피 성장 인자 수용체의 활성화 돌연변이체 형태의 퀴나졸린 억제제 |
CN106068262B (zh) * | 2014-04-11 | 2019-10-29 | 海思科医药集团股份有限公司 | 喹唑啉衍生物及其制备方法和在医药上的应用 |
AU2016343517B2 (en) * | 2015-10-19 | 2020-04-30 | Sunshine Lake Pharma Co., Ltd. | A salt of EGFR inhibitor, crystalline form and uses thereof |
CA3040348A1 (en) * | 2016-10-19 | 2018-04-26 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating cancer |
AU2017363199B2 (en) * | 2016-11-17 | 2023-08-17 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations |
WO2020053816A1 (en) | 2018-09-14 | 2020-03-19 | Hanmi Pharmaceutical Co., Ltd. | Crystalline forms of a quinazole compound and its hydrochloride salts |
-
2019
- 2019-09-12 WO PCT/IB2019/057720 patent/WO2020053816A1/en unknown
- 2019-09-12 BR BR112021004527-9A patent/BR112021004527A2/pt not_active Application Discontinuation
- 2019-09-12 SG SG11202102006YA patent/SG11202102006YA/en unknown
- 2019-09-12 JP JP2021514419A patent/JP2022500456A/ja active Pending
- 2019-09-12 CA CA3111062A patent/CA3111062A1/en active Pending
- 2019-09-12 CA CA3110369A patent/CA3110369A1/en active Pending
- 2019-09-12 KR KR1020217010772A patent/KR20210061371A/ko unknown
- 2019-09-12 US US17/275,382 patent/US11883402B2/en active Active
- 2019-09-12 WO PCT/US2019/050843 patent/WO2020056156A1/en unknown
- 2019-09-12 CN CN201980060160.6A patent/CN112770758A/zh active Pending
- 2019-09-12 US US17/275,290 patent/US20220040180A1/en not_active Abandoned
- 2019-09-12 EP EP19860538.8A patent/EP3849557A4/en not_active Withdrawn
- 2019-09-12 JP JP2021513941A patent/JP2022500416A/ja active Pending
- 2019-09-12 SG SG11202101712XA patent/SG11202101712XA/en unknown
- 2019-09-12 CN CN201980060170.XA patent/CN112823153A/zh active Pending
- 2019-09-12 AU AU2019337640A patent/AU2019337640A1/en not_active Abandoned
- 2019-09-12 EP EP19859287.5A patent/EP3849964A4/en active Pending
- 2019-09-12 MX MX2021002875A patent/MX2021002875A/es unknown
- 2019-09-12 MX MX2021002876A patent/MX2021002876A/es unknown
- 2019-09-12 AU AU2019340598A patent/AU2019340598A1/en active Pending
- 2019-09-12 BR BR112021004546-5A patent/BR112021004546A2/pt unknown
- 2019-09-12 KR KR1020217010957A patent/KR20210046818A/ko unknown
- 2019-09-16 TW TW108133290A patent/TW202027750A/zh unknown
- 2019-09-16 AR ARP190102610A patent/AR116669A1/es unknown
- 2019-09-16 UY UY0001038375A patent/UY38375A/es unknown
- 2019-09-16 UY UY0001038374A patent/UY38374A/es unknown
- 2019-09-16 AR ARP190102611A patent/AR116406A1/es unknown
- 2019-09-16 TW TW108133291A patent/TW202023562A/zh unknown
-
2021
- 2021-03-01 IL IL281167A patent/IL281167A/en unknown
- 2021-03-01 IL IL281168A patent/IL281168A/en unknown
- 2021-03-01 PH PH12021550432A patent/PH12021550432A1/en unknown
- 2021-03-03 PH PH12021550456A patent/PH12021550456A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR122787A2 (es) | Inhibidores de kras g12c y métodos para su uso | |
MY196582A (en) | PD-1/PD-L1 Inhibitors | |
MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
PE20170697A1 (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
BR112015021905A8 (pt) | métodoa para tratar uma formação subterrânea | |
AR116669A1 (es) | Kits y métodos para tratar cánceres | |
CL2021000650A1 (es) | Moduladores de la expresión de pnpla3 | |
PE20160192A1 (es) | Composiciones y metodo para tratar condiciones asociadas con el complemento | |
MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
EA202192575A1 (ru) | Соединения dbait в сочетании с ингибиторами киназ для лечения рака | |
CR20190471A (es) | Moduladores de la expresión de pcsk9 | |
PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
CO2023010023A2 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
EA201792288A1 (ru) | Способы лечения рака | |
MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
MX2019002673A (es) | Composiciones y metodos para tratar demencia. | |
UY38472A (es) | Moduladores de la expresión de foxp3 | |
CO2020003134A2 (es) | Moduladores de la expresión de enac | |
MX2021010603A (es) | Inhibidores de caspasa y metodos de uso de los mismos. | |
AR110998A1 (es) | Inhibidores de la tirosina cinasa de bruton | |
MX2021009423A (es) | Formas cristalinas de un inhibidor de la janocinasa 2 (jak2). | |
MX2021000895A (es) | Inhibidores de cinasas dependientes de ciclinas (cdk) y usos de los mismos. | |
MX2020010156A (es) | Inhibidores de la secrecion de proteina cdp. |